CY1122629T1 - Αιθυλεστερας εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας - Google Patents
Αιθυλεστερας εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιαςInfo
- Publication number
- CY1122629T1 CY1122629T1 CY20201100100T CY201100100T CY1122629T1 CY 1122629 T1 CY1122629 T1 CY 1122629T1 CY 20201100100 T CY20201100100 T CY 20201100100T CY 201100100 T CY201100100 T CY 201100100T CY 1122629 T1 CY1122629 T1 CY 1122629T1
- Authority
- CY
- Cyprus
- Prior art keywords
- hypertriglyceridemia
- treatment
- ethyl ester
- acid ethyl
- eicospentaenoic acid
- Prior art date
Links
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical class CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 208000006575 hypertriglyceridemia Diseases 0.000 title 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 abstract 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- G16Z99/00—Subject matter not provided for in other main groups of this subclass
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Σε διάφορες πραγματοποιήσεις, η παρούσα εφεύρεση παρέχει μεθόδους θεραπείας ή/και πρόληψης καρδιαγγειακών-σχετικών ασθενειών και ιδιαιτέρως μέθοδο θεραπείας λιπιδίου αίματος, που περιλαμβάνει χορήγηση σε ένα υποκείμενο, που έχει ανάγκη αυτής, μιας φαρμακευτικής σύνθεσης που περιλαμβάνει εικοσαπενταενοϊκό οξύ ή παράγωγο αυτού.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15129109P | 2009-02-10 | 2009-02-10 | |
US17375509P | 2009-04-29 | 2009-04-29 | |
EP10704464.6A EP2395991B1 (en) | 2009-02-10 | 2010-02-09 | Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia |
EP13156122.7A EP2596786B1 (en) | 2009-02-10 | 2010-02-09 | Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia |
PCT/US2010/023638 WO2010093634A1 (en) | 2009-02-10 | 2010-02-09 | Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1122629T1 true CY1122629T1 (el) | 2021-03-12 |
Family
ID=42102041
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100100T CY1122629T1 (el) | 2009-02-10 | 2020-02-04 | Αιθυλεστερας εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας |
CY20201100099T CY1122628T1 (el) | 2009-02-10 | 2020-02-04 | Χρηση αιθυλεστερα εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100099T CY1122628T1 (el) | 2009-02-10 | 2020-02-04 | Χρηση αιθυλεστερα εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας |
Country Status (24)
Country | Link |
---|---|
US (29) | US8293727B2 (el) |
EP (5) | EP3865128A1 (el) |
KR (2) | KR20140007973A (el) |
AU (1) | AU2010213899B2 (el) |
BR (1) | BRPI1007518A2 (el) |
CA (3) | CA3089847C (el) |
CY (2) | CY1122629T1 (el) |
DK (3) | DK3037089T3 (el) |
ES (3) | ES2768091T3 (el) |
HK (2) | HK1165698A1 (el) |
HR (3) | HRP20130811T1 (el) |
HU (1) | HUE048299T2 (el) |
LT (2) | LT3037089T (el) |
MX (1) | MX2011008448A (el) |
NZ (1) | NZ594395A (el) |
PH (1) | PH12015500407A1 (el) |
PL (3) | PL2395991T3 (el) |
PT (3) | PT2596786T (el) |
RU (2) | RU2505292C2 (el) |
SG (3) | SG10201610916SA (el) |
SI (3) | SI3037089T1 (el) |
SM (1) | SMT201300095B (el) |
WO (1) | WO2010093634A1 (el) |
ZA (1) | ZA201105612B (el) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
JP5924834B2 (ja) | 2008-09-02 | 2016-05-25 | アマリン ファーマシューティカルズ アイルランド リミテッド | エイコサペンタエン酸およびニコチン酸を含む製薬組成物ならびにこの製薬組成物を用いる方法 |
US9314444B2 (en) | 2009-01-12 | 2016-04-19 | Biokier, Inc. | Composition and method for treatment of NASH |
CN102355896A (zh) | 2009-01-12 | 2012-02-15 | 拜奥基尔公司 | 治疗糖尿病的组合物和方法 |
US9006288B2 (en) | 2009-01-12 | 2015-04-14 | Biokier, Inc. | Composition and method for treatment of diabetes |
PT2596786T (pt) | 2009-02-10 | 2020-03-04 | Amarin Pharmaceuticals Ie Ltd | Utilização de éster etílico de ácido eicosapentaenoico para tratamento de hipertrigliceridemia |
RU2489145C1 (ru) | 2009-04-29 | 2013-08-10 | АМАРИН КОРПОРЕЙШН ПиЭлСи | Фармацевтические композиции, содержащие ера и сердечно-сосудистое средство, и способ их применения |
BRPI1011876B1 (pt) | 2009-04-29 | 2020-03-31 | Amarin Pharma, Inc. | Composições farmacêuticas estáveis compreendendo etilácido eicosapentaenoico (etil-epa) e uso das mesmas para tratar ou prevenir uma doença relacionada ao cardiovascular |
SI3318255T1 (sl) * | 2009-06-15 | 2021-07-30 | Amarin Pharmaceuticals Ireland Limited | Kompozicije in metode za zdravljenje kapi pri subjektu, ki prejema sočasno zdravljenje s statinom |
SG10201405994UA (en) | 2009-09-23 | 2014-10-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same |
AU2010298303A1 (en) | 2009-09-23 | 2012-04-12 | Biokier, Inc. | Composition and method for treatment of diabetes |
US20110178105A1 (en) | 2010-01-15 | 2011-07-21 | E.I. Du Pont De Nemours And Company | Clinical benefits of eicosapentaenoic acid in humans |
CA3066588C (en) * | 2010-03-04 | 2022-03-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating and/or preventing cardiovascular disease |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
NZ778131A (en) * | 2010-11-29 | 2023-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
WO2013070735A1 (en) | 2011-11-07 | 2013-05-16 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
SI2800563T1 (sl) | 2012-01-06 | 2018-11-30 | Omthera Pharmaceuticals Inc. | Z DPA obogateni sestavki omega-3 polinenasičenih maščobnih kislin v obliki proste kisline |
US9827219B2 (en) | 2012-01-06 | 2017-11-28 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject |
AU2013200820B2 (en) * | 2012-02-14 | 2014-04-10 | Fermentalg | Method for supervising consumption of a medical food for prevention and/or management of a disease or condition |
US9492545B2 (en) | 2012-05-07 | 2016-11-15 | Omthera Pharmaceuticals Inc. | Compositions of statins and omega-3 fatty acids |
JP6254939B2 (ja) * | 2012-05-15 | 2017-12-27 | 持田製薬株式会社 | 高血中高感度c反応性蛋白質患者の心血管疾患一次予防剤 |
CA2916208A1 (en) | 2012-06-17 | 2013-12-27 | Matinas Biopharma, Inc. | Omega-3 pentaenoic acid compositions and methods of use |
US20140005265A1 (en) * | 2012-06-29 | 2014-01-02 | Amarin Pharmaceuticals Ireland Limited | Methods for treating hypertriglyceridemia |
WO2014004993A2 (en) * | 2012-06-29 | 2014-01-03 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing ldl-p |
US20140004183A1 (en) * | 2012-06-29 | 2014-01-02 | Amarin Pharmaceuticals Ireland Limited | Methods for treating cardiovascular disease in statin-tolerant subjects |
CA2877514A1 (en) | 2012-06-29 | 2014-01-03 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
EP2902020A4 (en) * | 2012-09-28 | 2016-03-23 | Mochida Pharm Co Ltd | COMPOSITION FOR REDUCING NEW DIABETES APPARITIONS |
US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
US10123986B2 (en) | 2012-12-24 | 2018-11-13 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
US9629820B2 (en) | 2012-12-24 | 2017-04-25 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US20140213648A1 (en) * | 2012-12-31 | 2014-07-31 | Amarin Pharmaceuticals Ireland Limited | Methods of increasing epa blood levels |
US20140221358A1 (en) * | 2013-02-06 | 2014-08-07 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof |
US20140221452A1 (en) * | 2013-02-06 | 2014-08-07 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and 5-htp and methods of use thereof |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
EP2968246A4 (en) * | 2013-03-13 | 2016-08-03 | Matinas Biopharma Inc | OMEGA 3 PENTANOIC ACID COMPOSITIONS AND METHODS OF USE |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
KR102039522B1 (ko) * | 2013-06-03 | 2019-11-26 | 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. | 근거리 무선 통신(nfc)을 이용한 nfc 태그의 기록방법 및 장치 |
US20140357717A1 (en) * | 2013-06-04 | 2014-12-04 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
JP6804823B2 (ja) * | 2013-10-14 | 2020-12-23 | アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティーArizona Board of Regents on behalf of Arizona State University | 白金錯体およびデバイス |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
WO2016175575A1 (ko) * | 2015-04-30 | 2016-11-03 | 엘지전자(주) | 블루투스 메쉬 네트워크를 이용하여 데이터를 송수신하기 위한 방법 및 장치 |
US10183044B2 (en) | 2015-05-15 | 2019-01-22 | P Tech, Llc | Systems and methods for thrombosis prevention |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
TW201900160A (zh) | 2017-05-19 | 2019-01-01 | 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 |
CA3080818A1 (en) | 2017-10-30 | 2019-05-09 | Montreal Heart Institute | Methods of treating elevated plasma cholesterol |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
SI4056176T1 (sl) | 2018-09-24 | 2024-09-30 | Amarin Pharmaceuticals Ireland Limited | Metode zmanjševanja tveganja za kardiovaskularne dogodke pri subjektu |
US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4377526A (en) * | 1981-05-15 | 1983-03-22 | Nippon Suisan Kaisha, Ltd. | Method of purifying eicosapentaenoic acid and its esters |
CA1239587A (en) | 1983-10-24 | 1988-07-26 | David Rubin | Combined fatty acid composition for lowering blood cholestrol and triglyceride levels |
US4526902A (en) * | 1983-10-24 | 1985-07-02 | Century Laboratories, Inc. | Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions |
JPS6135356A (ja) * | 1984-07-27 | 1986-02-19 | Nippon Oil & Fats Co Ltd | 血液脂質脂肪酸の分析方法 |
US4920098A (en) * | 1986-09-17 | 1990-04-24 | Baxter International Inc. | Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases |
US5252333A (en) * | 1987-04-27 | 1993-10-12 | Scotia Holdings Plc | Lithium salt-containing pharmaceutical compositions |
US5198468A (en) * | 1987-06-24 | 1993-03-30 | Efamol Holdings Plc | Essential fatty acid composition |
US4843095A (en) | 1987-08-07 | 1989-06-27 | Century Laboratories, Inc. | Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis |
GB8819110D0 (en) * | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
US5116871A (en) * | 1988-09-13 | 1992-05-26 | Efamol Holdings Plc | Fatty acid therapy and compositions for the treatment of myalgic encephalomyelitis |
GB2223943A (en) | 1988-10-21 | 1990-04-25 | Tillotts Pharma Ag | Oral disage forms of omega-3 polyunsaturated acids |
US4935243A (en) * | 1988-12-19 | 1990-06-19 | Pharmacaps, Inc. | Chewable, edible soft gelatin capsule |
JP2839276B2 (ja) * | 1989-01-23 | 1998-12-16 | 日本分光工業株式会社 | 超臨界流体抽出・分離方法及び装置 |
GB8906369D0 (en) | 1989-03-20 | 1989-05-04 | Tisdale Michael J | Eicosapentaenoic acid |
US5457130A (en) * | 1989-03-20 | 1995-10-10 | Cancer Research Campaign Technology Limited | Eicosapentaenoic acid used to treat cachexia |
CA2043615C (en) | 1990-06-04 | 2001-08-14 | Kazuhiko Hata | Method of producing eicosapentaenoic acid or the ester derivative thereof |
GB9012651D0 (en) * | 1990-06-06 | 1990-07-25 | Efamol Holdings | Essential fatty acid treatment |
JP3103588B2 (ja) | 1990-11-16 | 2000-10-30 | 持田製薬株式会社 | リポプロテイン(a)低下剤 |
SE9101642D0 (sv) | 1991-05-30 | 1991-05-30 | Kabi Pharmacia Ab | Phospholipids |
US5215630A (en) * | 1991-06-04 | 1993-06-01 | Nippon Suisan Kaisha, Ltd. | Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation |
WO1993003450A1 (en) * | 1991-07-30 | 1993-02-18 | North Carolina State University | Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy |
DE4133694C2 (de) * | 1991-10-11 | 1993-10-07 | Fresenius Ag | Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen |
JP3400466B2 (ja) | 1991-10-28 | 2003-04-28 | 日本水産株式会社 | 高純度エイコサペンタエン酸またはそのエステルの製造方法 |
JPH0649479A (ja) * | 1992-07-28 | 1994-02-22 | Maruha Corp | ω−3不飽和脂肪酸系化合物の安定化法 |
US5888541A (en) * | 1992-08-21 | 1999-03-30 | Scotia Holdings Plc | Fatty acid treatment |
GB9217780D0 (en) * | 1992-08-21 | 1992-10-07 | Efamol Holdings | Fatty acid treatment |
GB9300125D0 (en) | 1993-01-06 | 1993-03-03 | Scotia Holdings Plc | Compositions containing esters of unsaturated fatty acids |
WO1994028891A1 (en) | 1993-06-04 | 1994-12-22 | Martek Biosciences Corporation | Method of treating coronary vascular disease using docosahexaenoic acid |
GB9403857D0 (en) * | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
US5760081A (en) * | 1994-05-10 | 1998-06-02 | The General Hospital Corporation | Omega 3 fatty acids in the prevention of ventricular fibrillation |
AU711482B2 (en) * | 1994-06-28 | 1999-10-14 | Scotia Holdings Plc | Compositions for treatment of diabetic complications |
IT1274734B (it) * | 1994-08-25 | 1997-07-24 | Prospa Bv | Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti |
MY118354A (en) * | 1995-05-01 | 2004-10-30 | Scarista Ltd | 1,3-propane diol derivatives as bioactive compounds |
GB9519661D0 (en) * | 1995-09-27 | 1995-11-29 | Scotia Holdings Plc | Fatty acid treatment |
AU2738497A (en) | 1996-04-24 | 1997-11-12 | Brigham And Women's Hospital | Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder |
TW425285B (en) | 1996-06-10 | 2001-03-11 | Viva America Marketing Inc | Fish oil and garlic nutritive supplement |
US5861399A (en) * | 1996-07-17 | 1999-01-19 | Heart Care Partners | Methods and compositions for the rapid and enduring relief of inadequate myocardial function |
US20020055539A1 (en) * | 1996-10-02 | 2002-05-09 | Bockow Barry I. | Compositions and methods for treating cardiovascular conditions |
PL190181B1 (pl) * | 1996-10-11 | 2005-11-30 | Scarista Ltd | Zastosowanie oleju zawierającego kwas eikozapentaenowy (KEP) i/lub kwas stearydonowy (KS) oraz preparat farmaceutyczny zawierający olej |
US20010006644A1 (en) | 1997-07-31 | 2001-07-05 | David J. Bova | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
DE69825173T2 (de) * | 1997-10-30 | 2005-08-25 | Morishita Jintan Co. Ltd. | Doppelschichtige kapsel von ungesättigten fettsäuren oder deren derivate und verfahren zu deren herstellung |
CA2313024C (en) | 1997-12-10 | 2008-06-03 | Severson, Mary L. | Pharmaceutical compositions containing an omega-3 fatty acid oil |
US20020055529A1 (en) | 1998-12-02 | 2002-05-09 | Bisgaier Charles Larry | Method for treating alzheimer's disease |
GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
US20030104048A1 (en) * | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
US6193999B1 (en) * | 1999-03-01 | 2001-02-27 | Banner Pharmacaps, Inc. | Gum acacia substituted soft gelatin capsules |
ATE394941T1 (de) * | 1999-07-28 | 2008-05-15 | Swiss Caps Rechte & Lizenzen | Präparat zur verwendung als medikament und/oder nahrungsmittelergänzung |
AU6813700A (en) | 1999-08-30 | 2001-03-26 | Ocean Nutrition Canada Ltd. | A nutritional supplement for lowering serum triglyceride and cholesterol levels |
DE60022987T2 (de) | 2000-05-22 | 2006-10-19 | Pro Aparts - Investimentos E Consultoria Lda., Funchal | Fettsäurezusammensetzung, die wenigstens 80 Gew.-% EPA und DHA enthält |
GB0016045D0 (en) | 2000-06-29 | 2000-08-23 | Laxdale Limited | Therapeutic combinations of fatty acids |
CA2419406A1 (en) | 2000-08-15 | 2002-02-21 | Pfizer Products Inc. | Pharmaceutical combinations of torcetrapib and atorvastatin or hydroxy derivatives for the treatment of atherosclerosis, angina and low hdl levels |
ITMI20010129A1 (it) * | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
GB0111282D0 (en) | 2001-05-09 | 2001-06-27 | Laxdale Ltd | Potentiation of therapeutic effects of fatty acids |
NZ529339A (en) | 2001-05-30 | 2004-08-27 | Laxdale Ltd | Coenzyme Q and eicosapentaenoic acid (EPA) |
ITMI20012384A1 (it) * | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
ITMI20020269A1 (it) | 2002-02-12 | 2003-08-12 | Victorix Assets Ltd | Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca |
HUP0200686A2 (hu) | 2002-02-22 | 2003-09-29 | EURO- "H" Beruházásszervezż és Ingatlanhasznosító Kft. | Elektronikus berendezés és eljárás számsorozat eltalálására irányuló játékokban való részvételre kommunikációs berendezésen keresztül |
US20030166614A1 (en) * | 2002-03-01 | 2003-09-04 | Harrison Stanley F. | Method for reducing cholesterol and triglycerides |
CA2390820A1 (en) * | 2002-06-17 | 2003-12-17 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
AU2003257550A1 (en) * | 2002-08-20 | 2004-03-11 | Nikken Chemicals Co., Ltd. | Soft capsule preparation |
ZA200504059B (en) * | 2002-11-22 | 2007-12-27 | Nippon Susan Kaisha Ltd | External composition containing polyunsaturated fatty acid or its salt or ester |
GB0228079D0 (en) | 2002-12-02 | 2003-01-08 | Laxdale Ltd | Huntington's Disease |
AU2004216856A1 (en) | 2003-03-05 | 2004-09-16 | Solvay Pharmaceuticals Gmbh | Use of omega-3-fatty acids in the treatment of diabetic patients |
CN100415224C (zh) | 2003-03-18 | 2008-09-03 | 诺瓦提斯公司 | 包含脂肪酸和氨基酸的组合物 |
ITMI20032247A1 (it) | 2003-11-19 | 2005-05-20 | Tiberio Bruzzese | Interazione di derivati polari di composti insaturi con substrati inorganici |
GB2409644B (en) * | 2003-12-31 | 2005-12-21 | Igennus Ltd | Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof |
US7022713B2 (en) | 2004-02-19 | 2006-04-04 | Kowa Co., Ltd. | Hyperlipemia therapeutic agent |
US20050272095A1 (en) * | 2004-05-19 | 2005-12-08 | Ppd Biomarker Discovery Sciences, Llc | Methods of identifying biomarkers |
JP2007284350A (ja) | 2004-07-27 | 2007-11-01 | Takeda Chem Ind Ltd | 糖尿病治療剤 |
ITRM20040395A1 (it) | 2004-08-03 | 2004-11-03 | Sigma Tau Ind Farmaceuti | Composizione comprendente statine e acidi grassi omega 3. |
AU2005271413A1 (en) | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel statin pharmaceutical compositions and related methods of treatment |
EP1790338A4 (en) | 2004-09-13 | 2007-12-12 | Santen Pharmaceutical Co Ltd | THERAPEUTIC AGENT FOR KERATOCONJUNTIVA DISEASES |
CN1759834B (zh) * | 2004-09-17 | 2010-06-23 | 中国医学科学院医药生物技术研究所 | 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途 |
WO2006035417A2 (en) | 2004-09-27 | 2006-04-06 | Sigmoid Biotechnologies Limited | Dihydropyrimidine microcapsule - formulations |
JP5491697B2 (ja) | 2004-10-15 | 2014-05-14 | フォトンズ コーポレイション リミテッド | 高レベルオメガ−3および低レベル飽和脂肪酸を含む組成物 |
FR2878747B1 (fr) | 2004-12-03 | 2007-03-30 | Pierre Fabre Medicament Sa | Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih |
WO2006062748A2 (en) * | 2004-12-06 | 2006-06-15 | Reliant Pharmaceuticals, Inc. | Omega-3 fatty acids and dyslipidemic agent for lipid therapy |
US20070191467A1 (en) * | 2004-12-06 | 2007-08-16 | Reliant Pharmaceutical, Inc. | Statin and omega-3 fatty acids for lipid therapy |
US20060135610A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
GB2421909A (en) * | 2004-12-23 | 2006-07-12 | Laxdale Ltd | Pharmaceutical compositions comprising EPA and methods of use |
US20060189682A1 (en) * | 2005-02-02 | 2006-08-24 | Payne Joseph E | Water soluble prodrugs of COX-2 inhibitors |
EP1861087A4 (en) | 2005-03-08 | 2010-02-10 | Reliant Pharmaceuticals Inc | TREATMENT WITH STATINE AND OMEGA-3-FATTY ACID AS A COMBINATION PRODUCT THEREOF |
BRPI0613704A2 (pt) | 2005-07-08 | 2011-02-01 | Mochida Pharm Co Ltd | composição para impedir o inìcio e/ou a recorrência de eventos cardiovasculares |
RU2290185C1 (ru) * | 2005-07-26 | 2006-12-27 | Дмитрий Николаевич Мясников | Композиция для нормализации липидного обмена и снижения массы тела и способ её получения |
EA200800451A1 (ru) | 2005-07-28 | 2008-08-29 | Релайэнт Фармасьютикалз, Инк. | Лечение дигидропиридиновыми блокаторами кальциевых каналов и жирными кислотами омега-3 и их комбинированным продуктом |
ITMI20051560A1 (it) | 2005-08-10 | 2007-02-11 | Tiberio Bruzzese | Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6 |
EP1948168A4 (en) | 2005-10-28 | 2010-10-06 | Numerate Inc | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND / OR HMG-COA REDUCTASE |
US20070104779A1 (en) * | 2005-11-07 | 2007-05-10 | Rongen Roelof M | Treatment with omega-3 fatty acids and products thereof |
KR101292573B1 (ko) | 2005-11-11 | 2013-08-12 | 모치다 세이야쿠 가부시키가이샤 | 젤리 조성물 |
MX286464B (es) | 2005-12-20 | 2011-05-10 | Cenestra Llc | Formulaciones de acido graso omega 3. |
DK1800675T3 (da) | 2005-12-23 | 2011-09-05 | Nutricia Nv | Sammensætninger omfattende polyumættede fedtsyrer, proteiner og mangan og/eller molybdæn og nucleosider/nucleotider til behandling af demens |
WO2007091338A1 (ja) * | 2006-02-07 | 2007-08-16 | Mochida Pharmaceutical Co., Ltd. | 脳卒中再発予防用組成物 |
WO2007128801A1 (en) | 2006-05-08 | 2007-11-15 | Novartis Ag | Combination of organic compounds |
EP2022495B1 (en) | 2006-05-31 | 2014-07-23 | Mochida Pharmaceutical Co., Ltd. | Composition for preventing the occurrence of cardiovascular event in multiple risk patient |
NZ573719A (en) | 2006-07-05 | 2011-08-26 | Photonz Corp Ltd | Production of ultrapure eicosapentaenoic acid and polar lipids from largely heterotrophic culture of nitzschia laevis |
US20090304784A1 (en) * | 2006-07-28 | 2009-12-10 | V. Mane Fils | Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component |
CN101553221A (zh) | 2006-10-10 | 2009-10-07 | 瑞莱恩特医药品有限公司 | 用于降低APO-B水平的抑制素和ω-3脂肪酸 |
US20080125490A1 (en) * | 2006-11-03 | 2008-05-29 | My Svensson | Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids |
US20080306154A1 (en) | 2006-11-03 | 2008-12-11 | My Svensson | Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids |
CA2675836C (en) | 2007-01-17 | 2016-10-11 | Mochida Pharmaceutical Co., Ltd. | Composition for preventing or treating thrombus- or embolus-associated disease |
CA2677036A1 (en) | 2007-03-06 | 2008-09-12 | Bioriginal Food & Science Corp. | Soft gelatin capsule shells containing oil soluble flavoring and methods of making the same |
ES2748934T3 (es) | 2007-06-29 | 2020-03-18 | Takeda Pharmaceuticals Co | Cápsula sin costura |
US20090182049A1 (en) | 2008-01-16 | 2009-07-16 | Joar Arild Opheim | Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans |
JPWO2009142242A1 (ja) | 2008-05-20 | 2011-09-29 | 持田製薬株式会社 | ハイリスク患者の心血管イベント予防用組成物 |
JP5924834B2 (ja) | 2008-09-02 | 2016-05-25 | アマリン ファーマシューティカルズ アイルランド リミテッド | エイコサペンタエン酸およびニコチン酸を含む製薬組成物ならびにこの製薬組成物を用いる方法 |
PT2596786T (pt) | 2009-02-10 | 2020-03-04 | Amarin Pharmaceuticals Ie Ltd | Utilização de éster etílico de ácido eicosapentaenoico para tratamento de hipertrigliceridemia |
BRPI1011876B1 (pt) | 2009-04-29 | 2020-03-31 | Amarin Pharma, Inc. | Composições farmacêuticas estáveis compreendendo etilácido eicosapentaenoico (etil-epa) e uso das mesmas para tratar ou prevenir uma doença relacionada ao cardiovascular |
SI3318255T1 (sl) * | 2009-06-15 | 2021-07-30 | Amarin Pharmaceuticals Ireland Limited | Kompozicije in metode za zdravljenje kapi pri subjektu, ki prejema sočasno zdravljenje s statinom |
KR101579659B1 (ko) | 2010-11-04 | 2015-12-22 | 에프. 호프만-라 로슈 아게 | S-[2-([[1-(2-에틸부틸)-사이클로헥실]-카본일]아미노)페닐]2-메틸프로판티오에이트 및 크로스카멜로스 나트륨을 포함하는 조성물 |
US20140004183A1 (en) * | 2012-06-29 | 2014-01-02 | Amarin Pharmaceuticals Ireland Limited | Methods for treating cardiovascular disease in statin-tolerant subjects |
-
2010
- 2010-02-09 PT PT131561227T patent/PT2596786T/pt unknown
- 2010-02-09 US US12/702,889 patent/US8293727B2/en active Active
- 2010-02-09 BR BRPI1007518-6A patent/BRPI1007518A2/pt not_active Application Discontinuation
- 2010-02-09 ES ES13156122T patent/ES2768091T3/es active Active
- 2010-02-09 KR KR1020137034936A patent/KR20140007973A/ko not_active Application Discontinuation
- 2010-02-09 CA CA3089847A patent/CA3089847C/en active Active
- 2010-02-09 EP EP21152120.8A patent/EP3865128A1/en active Pending
- 2010-02-09 PL PL10704464T patent/PL2395991T3/pl unknown
- 2010-02-09 SI SI201031980T patent/SI3037089T1/sl unknown
- 2010-02-09 PT PT107044646T patent/PT2395991E/pt unknown
- 2010-02-09 SG SG10201610916SA patent/SG10201610916SA/en unknown
- 2010-02-09 MX MX2011008448A patent/MX2011008448A/es active IP Right Grant
- 2010-02-09 WO PCT/US2010/023638 patent/WO2010093634A1/en active Application Filing
- 2010-02-09 RU RU2011137415/15A patent/RU2505292C2/ru active
- 2010-02-09 EP EP10704464.6A patent/EP2395991B1/en not_active Revoked
- 2010-02-09 EP EP16152447.5A patent/EP3037089B1/en not_active Revoked
- 2010-02-09 LT LTEP16152447.5T patent/LT3037089T/lt unknown
- 2010-02-09 PL PL13156122T patent/PL2596786T3/pl unknown
- 2010-02-09 SI SI201030313T patent/SI2395991T1/sl unknown
- 2010-02-09 NZ NZ594395A patent/NZ594395A/en unknown
- 2010-02-09 SI SI201031979T patent/SI2596786T1/sl unknown
- 2010-02-09 CA CA2751576A patent/CA2751576C/en active Active
- 2010-02-09 HU HUE16152447A patent/HUE048299T2/hu unknown
- 2010-02-09 ES ES16152447T patent/ES2769926T3/es active Active
- 2010-02-09 EP EP19193487.6A patent/EP3616694A1/en not_active Withdrawn
- 2010-02-09 AU AU2010213899A patent/AU2010213899B2/en active Active
- 2010-02-09 DK DK16152447.5T patent/DK3037089T3/da active
- 2010-02-09 ES ES10704464T patent/ES2426132T3/es active Active
- 2010-02-09 PL PL16152447T patent/PL3037089T3/pl unknown
- 2010-02-09 PT PT161524475T patent/PT3037089T/pt unknown
- 2010-02-09 EP EP13156122.7A patent/EP2596786B1/en not_active Revoked
- 2010-02-09 KR KR1020117019164A patent/KR101383006B1/ko active IP Right Grant
- 2010-02-09 DK DK10704464.6T patent/DK2395991T3/da active
- 2010-02-09 DK DK13156122.7T patent/DK2596786T3/da active
- 2010-02-09 LT LTEP13156122.7T patent/LT2596786T/lt unknown
- 2010-02-09 SG SG10201400685SA patent/SG10201400685SA/en unknown
- 2010-02-09 SG SG2011057353A patent/SG173612A1/en unknown
- 2010-02-09 CA CA3008079A patent/CA3008079C/en active Active
-
2011
- 2011-07-29 ZA ZA2011/05612A patent/ZA201105612B/en unknown
- 2011-08-04 US US13/198,221 patent/US20110288171A1/en not_active Abandoned
- 2011-10-26 US US13/282,145 patent/US8318715B2/en active Active
- 2011-10-28 US US13/284,408 patent/US8314086B2/en active Active
-
2012
- 2012-01-12 US US13/349,157 patent/US8415335B2/en active Active
- 2012-01-12 US US13/349,150 patent/US8324195B2/en active Active
- 2012-01-12 US US13/349,153 patent/US8293728B2/en active Active
- 2012-02-23 US US13/403,694 patent/US20120156285A1/en not_active Abandoned
- 2012-02-24 US US13/404,666 patent/US20120157530A1/en not_active Abandoned
- 2012-05-29 US US13/482,720 patent/US20120237594A1/en not_active Abandoned
- 2012-06-21 HK HK12106100.0A patent/HK1165698A1/xx not_active IP Right Cessation
- 2012-09-10 US US13/608,775 patent/US8357677B1/en active Active
- 2012-09-10 US US13/608,744 patent/US8426399B2/en active Active
- 2012-09-11 US US13/610,247 patent/US8367652B2/en active Active
- 2012-09-11 US US13/610,217 patent/US8399446B2/en active Active
- 2012-09-20 US US13/623,450 patent/US8377920B2/en active Active
- 2012-12-11 US US13/711,329 patent/US8431560B1/en active Active
- 2012-12-11 US US13/711,324 patent/US8440650B1/en active Active
-
2013
- 2013-02-25 US US13/776,261 patent/US8546372B2/en active Active
- 2013-02-25 US US13/776,242 patent/US8518929B2/en active Active
- 2013-02-25 US US13/776,249 patent/US8524698B2/en active Active
- 2013-05-28 US US13/903,742 patent/US20130331447A1/en not_active Abandoned
- 2013-08-29 HR HRP20130811AT patent/HRP20130811T1/hr unknown
- 2013-09-05 SM SM201300095T patent/SMT201300095B/xx unknown
- 2013-12-10 RU RU2013154780A patent/RU2686315C2/ru active
-
2015
- 2015-02-25 PH PH12015500407A patent/PH12015500407A1/en unknown
-
2016
- 2016-12-23 HK HK16114664A patent/HK1226307A1/zh unknown
-
2017
- 2017-01-17 US US15/408,077 patent/US20170119722A1/en not_active Abandoned
-
2018
- 2018-02-28 US US15/907,707 patent/US20180185320A1/en not_active Abandoned
- 2018-07-06 US US16/029,198 patent/US20190038590A1/en not_active Abandoned
-
2020
- 2020-01-16 HR HRP20200065TT patent/HRP20200065T1/hr unknown
- 2020-01-16 HR HRP20200068TT patent/HRP20200068T1/hr unknown
- 2020-02-04 CY CY20201100100T patent/CY1122629T1/el unknown
- 2020-02-04 CY CY20201100099T patent/CY1122628T1/el unknown
- 2020-04-21 US US16/854,757 patent/US20200246300A1/en not_active Abandoned
- 2020-09-01 US US17/009,597 patent/US20210046036A1/en not_active Abandoned
- 2020-11-23 US US17/101,700 patent/US20210069142A1/en not_active Abandoned
-
2021
- 2021-01-20 US US17/153,494 patent/US20210251941A1/en not_active Abandoned
-
2023
- 2023-02-24 US US18/174,091 patent/US20240024277A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122629T1 (el) | Αιθυλεστερας εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας | |
CY1123549T1 (el) | Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης | |
CY1123749T1 (el) | Μεθοδοι μειωσης του κινδυνου καρδιαγγειακου γεγονοτος σε ενα υποκειμενο επι θεραπειας στατινης χρησιμοποιωντας αιθυλ εστερα εικοσαπενταενοϊκου οξεος | |
CY1124103T1 (el) | Δοσολογικο σχημα που σχετιζεται με ενεσιμους εστερες παλιπεριδονης μακρας δρασης | |
CY1120102T1 (el) | Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης | |
CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
CY1117869T1 (el) | Φαρμακοτεχνικες μορφες για απο του στοματος απελευθερωση προσροφητικων στο εντερο | |
EA201101111A1 (ru) | Алкиламинозамещенные дицианопиридины и их пролекарства в виде сложных эфиров с аминокислотами | |
CY1122809T1 (el) | Εστερικα προ-φαρμακα της [3-(1-(1η-ιμιδαζολ-4-υλ)αιθυλο)-2-μεθυλοφαινυλο) μεθανολης για τη θεραπεια οφθαλμικων νοσηματων | |
CO6351803A2 (es) | Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi) | |
BRPI0915300C1 (pt) | compostos de éster boronato e composições farmacêuticas dos mesmos | |
EA201491726A1 (ru) | Конъюгаты бороновых кислот олигонуклеотидных аналогов | |
CY1120094T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει despr036 eξenδinh-4(1-39)-lys6-nh2 για χρηση στην θεραπευτικη αγωγη μιας νευροεκφυλιστικης ασθενειας | |
EA201270071A1 (ru) | Способ лечения пациента, нуждающегося в аспириновой терапии | |
AR088585A1 (es) | Un medicamento para tratar la enfermedad del ojo anterior | |
CY1114760T1 (el) | Θεραπευτικη αγωγη αθηροσκληρωσης | |
CY1117483T1 (el) | Συνθεσεις τροποποιημενης αποδεσμευσης επαλρεστατης ή ενος παραγωγου αυτης και μεθοδοι για χρηση των ιδιων | |
EA201270747A1 (ru) | Композиции и способы для профилактики и лечения ран | |
EA201270176A1 (ru) | Производные тазаротена | |
EA201500765A1 (ru) | Способы лечения сердечно-сосудистых заболеваний | |
UA109359C2 (xx) | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
CY1116088T1 (el) | Δοκοζαεξανοϊκος πανθενυλεστερας και χρηση αυτου για θεραπεια και αποτροπη καρδιαγγειακων ασθενειων | |
CY1114276T1 (el) | Χρηση αιθυλεστερα εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας | |
CY1119845T1 (el) | Ενα γαλακτοκομικο προϊον μειωμενης χοληστερολης για χρηση στην θεραπευτικη αντιμετωπιση και/ή προληψη μιας ασθενειας του ηπατος | |
CY1115204T1 (el) | Παραγωγα νεων υπεροξειδιων, μεθοδος παρασκευης τους και η χρηση τους στην ανθρωπινη ιατρικη καθως επισης και στα καλλυντικα για τη θεραπεια ή την προληψη της ακμης |